- Investors & Media
- Investors & Media
- Contact Us
The Company has announced that it is examining the possibility of a public offering of its ordinary shares in the United States and the listing thereof on a U.S. stock exchange. As of the date of this press release, the Company has not made any decision regarding the basic terms of the potential offering, including […]
Kamada presents positive results of measurements of efficacy and safety in a unique clinical trial, for the treatment of type 1 (juvenile onset) diabetes, with its Alpha-1 Antitrypsin (AAT) protein.
Revenues at $17.7 million,
Operating profit at $1.3 million.
An increase of 33% in revenues in the first 9 months of 2012 to $51 million.
An increase of 39% in Kamada's manufactured products sector revenues in the first 9 months of 2012 to approximately $30.5 million.
Annual revenues forecast of $72 million reflects continued growth and record revenues forecast for Q4 of 2012.
The AAT Protein in Kamada's Glassia Drug Shows Promise in a Series of Studies that Demonstrate Prevention of Lung Infection and Successful Organ Transplantation:
In several pre-clinical studies performed in Ben Gurion University, lead by Dr Eli Lewis, the Glassia drug by Kamada shows new therapeutic capabilities including being a potential treatment to bacterial lung infection, serving as a strog anti inflammatory agent in COPD and prevention of transplant rejection.
Furthermore, results of Glassia phase 2 study in Type 1 Diabetes (T1D) are expected to be published during the course of this month.
Completion of recruitment was upon meeting the statistical data collection goals required for the study efficacy measures.
The trial will be completed during Q4 2013.
EMA supports Kamada in an open label extension treatment for patients who have completed their trial participation.
David Tsur, Kamada CEO: Completing patient recruitment is a significant achievement for Kamada, further strengthening its position as a global leader in developing the inhaled Alpha-1 antitrypsin”.
Kamada is currently evaluating strategic collaborations for conducting the Phase II clinical trial in the US.
The Phase II/III trial of AATD-IH, which is already underway in Europe and its results are expected late 2013, may serve the drug approval application to FDA, together with the data from the Phase II study of this IND Approval .
Kamada and Chiesi enter into a strategic agreement for the distribution of Kamada's inhaled AAT drug for treatment of Alpha-1 antitrypsin deficiency in Europe, Turkey and former CIS countries.
The trial is testing an innovative breakthrough treatment for Type 1 diabetes, which does not use the only current treatments of insulin and diet. D1-AAT may slow progression of the disease, and may greatly reduce, or completely eliminate, the need for insulin. This will stabilize the condition of diabetics and/or reduce or prevent serious complications of the disease.
Kamada Ltd. (TASE: KMDA) has obtained Food and Drug Administration (FDA) approval to conduct a clinical trial in the US for the company's next generation drug – an inhalable version of AAT (Alpha-1 Antitrypsin deficiency) for the treatment of cystic fibrosis.
This is the second patent issued to Kamada under the same title after being granted with the same patent title by the United States Patent Office (USPTO).